Each member of the team at Genesys Capital brings significant knowledge and expertise in the high technology and biotechnology sectors.

Management

Kelly Holman | Co-Founder and Managing Director

Mr. Holman is co-Founder and Managing Director of Genesys Capital and has extensive commercial and technical experience in the biotechnology industry. Since co-founding Genesys Capital in 2000, Mr. Holman has been actively involved in raising over $300 million of venture capital and has been instrumental in deploying over $160 million across 29 investments. He currently serves on the Board of Directors of Functional Neuromodulation Ltd. and from 2012-2015, he was a board observer with Invitae. From 2001 to 2013, he served on the board of Epocal, a Genesys portfolio company acquired by Alere (NYSE: ALR). Mr. Holman also sits on the Board of Directors of the Ontario Biotechnology Innovation Organization (OBIO)

Prior to co-founding Genesys Capital, Mr. Holman was a Senior Investment Manager with MDS Capital Corporation. Previously, Mr. Holman worked in the laboratory of Dr. Peter St George-Hyslop at the University of Toronto where he was a key member of the international research team that discovered several genes responsible for Alzheimer's disease. Mr. Holman holds a Bachelor of Science (Honours) in Biochemistry and an MBA, both from Queen's University.

Damian Lamb | Co-Founder and Managing Director

Mr. Lamb is co-Founder and Managing Director of Genesys Capital. He brings a unique experience base, blending skills in both the commercial and technical side of biotechnology. Since co-founding Genesys Capital in 2000, Mr. Lamb has been instrumental in raising over $300 million in venture capital funds, and has been involved in deploying over $160 million across 29 investments. He currently serves on the Boards of Affinium Pharmaceuticals Inc., Fusion Pharmaceuticals, Profound Medical Inc. (TSX: PRN) and the Centre for Probe Development and Commercialization at McMaster University. He has served on the Board of Ionalytics Corporation (acquired by Thermo Electron Corp.), Millenium Biologix (acquired by Medtronic) and was Chairman of the Board of DELEX Therapeutics Inc. when it was sold to YM BioSciences (now Gilead). Mr. Lamb works closely with Genesys investee companies to strategically position the companies to build value for shareholders.

Prior to co-founding Genesys Capital, Mr. Lamb was an Investment Manager with MDS Capital Corp. He is a frequently invited speaker at biotechnology industry conferences.

Mr. Lamb graduated from McMaster University, Faculty of Health Sciences, with a Master of Science in Molecular Neurobiology and also holds an MBA from Queen's University.

Jamie Stiff | Partner

Mr. Stiff joined Genesys Capital in 2002 and became partner at the firm in 2007 and Managing Director in 2016. During his tenure with Genesys, he has been responsible for investments in nine early stage portfolio companies that cross a multitude of clinical disciplines and technology areas. Past board affiliations include Allostera Pharma Inc., gIcare Pharma Inc., Interface Biologics, Inc., Matregen Corp, Naurex Inc. (acquired by Allergan NYSE:AGN), NeurAxon Inc., StemPath Inc., Therapeutic Monitoring Systems Inc. and Zelos Therapeutics Inc.

Prior to joining Genesys, Mr. Stiff worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics arena. This experience, combined with an academic background in biology, has provided significant technical knowledge of many areas of life sciences. Mr. Stiff completed a Bachelor of Science (Honours) from Queen's University and an MBA from the Rotman School of Management.

Jennifer Williams | Director of Finance and Operations

Ms. Williams is Director of Finance and Operations and joined Genesys Capital in 2002. Ms. Williams brings to Genesys a well-balanced range of skills. She has a proven track record of success in implementing a variety of major projects, and in working with senior stakeholders and key contacts. During her career with Genesys she has worked closely with the team to develop the operations and is responsible for finance and administration.

Ms. Williams graduated from the University of Guelph with an Honours Bachelor of Commerce and holds an MBA from Queen's University.

Lisa Low | Chief Financial Officer

Ms. Low joined Genesys Capital in 2007 in the role of Chief Financial Officer. Ms. Low has more than twenty years of experience in finance and administration within the investment management industry.

Ms. Low is also a finance executive with Covington Capital Corporation, a provider of venture capital investment funds where she is involved in finance, operations, administration and compliance within the firm. Covington manages over $150 million in retail venture capital funds and other investment vehicles.

Ms. Low is a CPA, CA and holds a Master of Accounting degree from the University of Waterloo.

Patricia Vettirajah | Office Manager

Ms. Vettirajah joined Genesys Capital in 2007 as an Executive Assistant. She currently supports and complements the responsibilities of the Director of Finance and Operations. She is also responsible for organizing key stakeholder meetings including the annual Genesys Symposium and the annual meetings for the funds. Prior to joining Genesys, Ms. Vettirajah worked with Endpoint Research, a Clinical Research Organization, in the capacity of Quality Assurance and Training Coordinator.

Ms. Vettirajah graduated from York University with a BA in Liberal Studies (Business). She is currently pursuing her Certified Human Resources Professional (CHRP) designation with the Human Resources Professionals Association.

Venture Partners

Kenneth Galbraith | Venture Partner

Ken Galbraith is a Venture Partner at Genesys Capital and Managing Director of Five Corners Capital.

Ken Galbraith joined Ventures West as a General Partner in 2007 and led the firm’s biotech practice prior to founding Five Corners Capital in 2013 to continue management of the Ventures West investment portfolio. Ken is a well-known and active member of the North American life sciences community with over 25 years of experience acting as an executive, director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors.

Previously, Mr. Galbraith served as the Chairman and Interim CEO of AnorMED, a biopharmaceutical company focused on new therapeutic products in hematology, HIV and oncology, until its sale to Genzyme Corp. in a cash transaction worth almost US$600 million. Starting in the biotech sector in 1987, Mr. Galbraith spent 13 years in senior management with QLT Inc., a global biopharmaceutical company specializing in developing treatments for eye diseases and oncology, retiring in 2000 from his position as Executive VP and CFO when QLT’s market capitalization exceeded US$5 billion. He has served on the Board of Directors of several public and private biotechnology companies, including Angiotech Pharmaceuticals (ANPI), Tekmira (TKMR) and Cardiome Pharma (CRME). He currently serves on the Board of Directors of Macrogenics (MGNX), Zymeworks, Augurex and AudienceView Ticketing Software.

Ken earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985 and appointed a Fellow of the Chartered Accountants of BC in 2013.

Stuart Collinson | Venture Partner

Stuart Collinson is a venture partner at Genesys Capital, and Executive Chairman of Tioga Pharmaceuticals and Arcturus Therapeutics.

Previously he was Chairman and CEO of Aurora Biosciences (acquired by Vertex Pharmaceuticals). He held senior management positions at GlaxoWellcome (now GlaxoSmithKline) and Baxter International, and was a consultant with The Boston Consulting Group.

Dr. Collinson has also been the chairman and director of several private companies including Affinium Pharmaceuticals (acquired by Debiopharm), NovaCardia (acquired by Merck & Co), Conforma Therapeutics (acquired by Biogen), GeneOhm Sciences (acquired by Becton Dickinson), Cabrellis Pharmaceuticals (acquired by Pharmion, now part of Celgene), Essentialis (acquired by Capnia), and Proprius Pharmaceuticals (acquired by Cypress Biosciences).

Dr. Collinson received an MBA from Harvard Business School and a PhD (DPhil) in Physical Chemistry from the University of Oxford.